ECSP14013264A - Nuevos derivados bicíclicos de dihidroquinolina-2-ona - Google Patents

Nuevos derivados bicíclicos de dihidroquinolina-2-ona

Info

Publication number
ECSP14013264A
ECSP14013264A ECSP14013264A ECSP14013264A EC SP14013264 A ECSP14013264 A EC SP14013264A EC SP14013264 A ECSP14013264 A EC SP14013264A EC SP14013264 A ECSP14013264 A EC SP14013264A
Authority
EC
Ecuador
Prior art keywords
dihidroquinolina
ona
bicyclic derivatives
new bicyclic
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Mohr
Kurt Amrein
Alexander V Mayweg
Hans Peter Maerki
Aurel Johannes Aebi
Benoit Hornsperger
Bernd Kuhn
Serena Maria Fantasia
Yongfu Liu
Michelangelo Scalone
Xuefei Tan
Mingwei Zhou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP14013264A publication Critical patent/ECSP14013264A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona nuevos compuestos que poseen la fórmula general (I) (I)en el que R1, R2, R3, R4¸ R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 A3 y n son tal como se ha descrito aquí, las composiciones que incluyen los compuestos y los métodos para utilizar los compuestos.
ECSP14013264 2011-09-23 2014-03-21 Nuevos derivados bicíclicos de dihidroquinolina-2-ona ECSP14013264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011080078 2011-09-23

Publications (1)

Publication Number Publication Date
ECSP14013264A true ECSP14013264A (es) 2014-04-30

Family

ID=46963698

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013264 ECSP14013264A (es) 2011-09-23 2014-03-21 Nuevos derivados bicíclicos de dihidroquinolina-2-ona

Country Status (34)

Country Link
US (1) US9353081B2 (es)
EP (1) EP2758388B1 (es)
JP (1) JP6012737B2 (es)
KR (1) KR101723276B1 (es)
CN (1) CN103827101B (es)
AR (1) AR087984A1 (es)
AU (1) AU2012311582B2 (es)
BR (1) BR112014006660B1 (es)
CA (1) CA2845170C (es)
CL (1) CL2014000663A1 (es)
CO (1) CO6870035A2 (es)
CR (1) CR20140089A (es)
DK (1) DK2758388T3 (es)
EA (1) EA035108B1 (es)
EC (1) ECSP14013264A (es)
ES (1) ES2666802T3 (es)
HR (1) HRP20180592T1 (es)
HU (1) HUE038773T2 (es)
IL (1) IL230874A (es)
LT (1) LT2758388T (es)
MX (1) MX366095B (es)
MY (1) MY186165A (es)
NO (1) NO2758388T3 (es)
PE (2) PE20181378A1 (es)
PH (1) PH12014500584A1 (es)
PL (1) PL2758388T3 (es)
PT (1) PT2758388T (es)
RS (1) RS57139B1 (es)
SG (1) SG2014010599A (es)
SI (1) SI2758388T1 (es)
TW (1) TWI576342B (es)
UA (1) UA115972C2 (es)
WO (1) WO2013041591A1 (es)
ZA (1) ZA201401577B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
HUE035274T2 (en) * 2012-04-17 2018-05-02 Hoffmann La Roche New phenyl tetrahydroisoquinoline derivatives
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
MX2015011005A (es) * 2013-03-14 2015-10-22 Hoffmann La Roche Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.
RU2693698C2 (ru) * 2013-05-27 2019-07-04 Ф. Хоффманн-Ля Рош Аг Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она
WO2014191338A1 (en) * 2013-05-27 2014-12-04 F. Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
AR096423A1 (es) * 2013-05-27 2015-12-30 Hoffmann La Roche Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
CN105593212B (zh) * 2013-10-17 2019-06-04 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
CN105531263B (zh) * 2013-10-17 2019-08-23 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
CN106660998B (zh) * 2014-10-31 2019-10-25 豪夫迈·罗氏有限公司 吡唑基-3,4-二氢喹啉-2-酮醛固酮合酶抑制剂
WO2016066662A1 (en) * 2014-10-31 2016-05-06 F. Hoffmann-La Roche Ag New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors
EP3212630B1 (en) * 2014-10-31 2022-05-18 F. Hoffmann-La Roche AG New dihydroquinoline pyrazolyl compounds
WO2016089800A1 (en) * 2014-12-02 2016-06-09 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
JPWO2017213247A1 (ja) 2016-06-10 2019-04-04 日本メジフィジックス株式会社 心疾患の非侵襲的画像診断剤
CN113767095A (zh) 2019-05-01 2021-12-07 勃林格殷格翰国际有限公司 (r)-4-溴苯磺酸(2-甲基环氧乙烷-2-基)甲酯
JP2024523559A (ja) * 2021-06-24 2024-06-28 シンコア・ファーマ・インコーポレイテッド アルドステロン合成酵素阻害剤を使用する方法
WO2023063851A1 (en) * 2021-10-13 2023-04-20 «Target Medicals» Limited Liability Company Inhibitors of human aldosterone synthase (cyp11b2)
AU2022415313A1 (en) 2021-12-14 2024-05-02 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
CN119789855A (zh) 2022-09-02 2025-04-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物
CN119894905A (zh) * 2022-09-23 2025-04-25 广州威诺森医药科技有限公司 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用
JP2025540715A (ja) * 2022-11-23 2025-12-16 上▲海▼翰森生物医▲薬▼科技有限公司 ピリジン多環系化合物阻害剤、及びその製造方法と使用
CN120359210A (zh) * 2023-04-28 2025-07-22 长春金赛药业有限责任公司 Cyp11b2抑制剂化合物、药物组合物及其应用
KR20260009903A (ko) * 2023-05-12 2026-01-20 장쑤 더위안 파머슈티컬 코.,엘티디. 질소 함유 헤테로사이클릭 화합물 및 그의 용도
JP2026521801A (ja) * 2023-06-29 2026-07-01 アストラゼネカ アイルランド リミテッド バクスドロスタットの結晶形、並びにその製造方法及びその使用
CN121586708A (zh) * 2023-07-21 2026-02-27 上海翰森生物医药科技有限公司 三并环类化合物、及其制备方法和应用
KR20260074307A (ko) 2023-09-05 2026-05-22 이-스타 바이오텍, 엘엘씨 Manp의 제형 및 이의 용도
CN117247371B (zh) * 2023-09-18 2026-03-10 上海相辉医药科技有限公司 一种cyp11b2抑制剂baxdrostat的制备方法
WO2025098465A1 (zh) * 2023-11-10 2025-05-15 上海齐鲁制药研究中心有限公司 稠环衍生物、其制备方法及其在医药上的应用
IL329013A (en) 2023-12-15 2026-08-01 Astrazeneca Ireland Ltd SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension
AU2024414094A1 (en) 2023-12-29 2026-07-16 Shenzhen Salubris Pharmaceuticals Co., Ltd Aldosterone synthetase inhibitor, and preparation method therefor and use thereof
CN120289471B (zh) * 2024-03-01 2025-10-17 浙江扬厉医药技术有限公司 吡喃并吡啶类化合物、其制备方法、药物组合物及应用
WO2025256482A1 (zh) * 2024-06-12 2025-12-18 江苏德源药业股份有限公司 一种吡啶并环类化合物及其制备和应用
CN121181527A (zh) * 2024-06-21 2025-12-23 江苏豪森药业集团有限公司 双稠环类化合物、及其制备方法和应用
WO2026093586A1 (en) 2024-11-04 2026-05-07 AstraZeneca Ireland Limited Combination of a aldosterone synthase inhibitor (asi) and a sodium-glucose co-transporter 2 inhibitor (sglt2i) for use in methods of reducing the risk of cardiovascular and heart failure events in a subject
WO2026138971A1 (zh) * 2024-12-26 2026-07-02 深圳信立泰药业股份有限公司 一种化合物a或其盐的医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
GB8709448D0 (en) * 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
WO2005065050A2 (ja) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation 2環化合物
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2

Also Published As

Publication number Publication date
KR20140076591A (ko) 2014-06-20
MX366095B (es) 2019-06-27
PE20181378A1 (es) 2018-09-05
JP6012737B2 (ja) 2016-10-25
EA035108B1 (ru) 2020-04-28
US20130079365A1 (en) 2013-03-28
ZA201401577B (en) 2015-01-28
UA115972C2 (uk) 2018-01-25
AU2012311582A1 (en) 2014-02-20
NZ620652A (en) 2016-09-30
DK2758388T3 (en) 2018-05-07
MX2014002624A (es) 2014-04-14
CL2014000663A1 (es) 2014-10-03
CO6870035A2 (es) 2014-02-20
CN103827101A (zh) 2014-05-28
JP2014526539A (ja) 2014-10-06
LT2758388T (lt) 2018-05-10
SI2758388T1 (en) 2018-05-31
CA2845170C (en) 2019-08-13
WO2013041591A1 (en) 2013-03-28
KR101723276B1 (ko) 2017-04-04
SG2014010599A (en) 2014-04-28
PH12014500584A1 (en) 2017-04-26
TWI576342B (zh) 2017-04-01
AR087984A1 (es) 2014-04-30
NO2758388T3 (es) 2018-07-21
PE20141042A1 (es) 2014-08-27
CN103827101B (zh) 2016-12-07
EP2758388A1 (en) 2014-07-30
RS57139B1 (sr) 2018-07-31
US9353081B2 (en) 2016-05-31
PT2758388T (pt) 2018-04-17
ES2666802T3 (es) 2018-05-07
IL230874A (en) 2016-07-31
MY186165A (en) 2021-06-30
CR20140089A (es) 2014-03-21
CA2845170A1 (en) 2013-03-28
PL2758388T3 (pl) 2018-08-31
HRP20180592T1 (hr) 2018-05-18
TW201319054A (zh) 2013-05-16
IL230874A0 (en) 2014-03-31
BR112014006660A2 (pt) 2017-04-04
BR112014006660B1 (pt) 2021-08-17
EA201490567A1 (ru) 2014-07-30
AU2012311582B2 (en) 2017-07-06
EP2758388B1 (en) 2018-02-21
HUE038773T2 (hu) 2018-11-28

Similar Documents

Publication Publication Date Title
CR20140089A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
CU24309B1 (es) Compuestos derivados tienopirimidina y composiciones farmacéuticas que los contienen
MX2017004541A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa.
CL2017002452A1 (es) Nuevos compuestos bicíclicos
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY36734A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170573A (es) Lactamas bicíclicas y métodos de uso de las mismas
CR20140135A (es) Nuevos derivados de aril-quinolina
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CR20140275A (es) Triazolopiridinas sustituidas
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
ECSP14013215A (es) Compuestos novedosos
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
MX343225B (es) Nuevos derivados de aril-benzocicloalquil-amida.
ECSP17069696A (es) Compuestos novedosos
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
CU20160010A7 (es) NUEVOS COMPUESTOS ISOINDOLlNA O ISOQUINOLlNA ÚTILES COMO INHIBIDORES ANTIAPOPTÓTICOS Bcl-2 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN